S-606001 + Placebo
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pompe Disease
Conditions
Pompe Disease
Trial Timeline
Oct 30, 2025 → Aug 8, 2027
NCT ID
NCT07123155About S-606001 + Placebo
S-606001 + Placebo is a phase 2 stage product being developed by Shionogi for Pompe Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07123155. Target conditions include Pompe Disease.
What happened to similar drugs?
10 of 17 similar drugs in Pompe Disease were approved
Approved (10) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07123155 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pompe Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| alglucosidase alfa | Sanofi | Approved | 43 |
| GZ402666 | Sanofi | Phase 1 | 29 |
| alglucosidase alfa + Placebo | Sanofi | Phase 3 | 40 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| glucosidase alfa | Sanofi | Pre-clinical | 26 |
| Alglucosidase alfa | Sanofi | Approved | 35 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 35 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| Myozyme | Sanofi | Phase 3 | 40 |
| alglucosidase alfa | Sanofi | Approved | 43 |
| alglucosidase alfa | Sanofi | Pre-clinical | 26 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 40 |
| Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa) | Sanofi | Approved | 35 |
| ALGLUCOSIDASE ALFA | Sanofi | Approved | 43 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 35 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 39 |
| Myozyme | Sanofi | Phase 2 | 35 |
| Myozyme | Sanofi | Phase 2 | 35 |
| recombinant human acid alpha-glucosidase (rhGAA) | Sanofi | Phase 2 | 35 |
| Alglucosidase Alfa + Methotrexate + Rituximab | Sanofi | Approved | 43 |